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Abstract Rapid bacterial species identification and antibiotic
susceptibility testing in positive blood cultures have an impor-
tant impact on the antibiotic treatment for patients. To identify
extended-spectrum beta-lactamases (ESBL) directly in posi-
tive blood culture bottles, we developed a workflow of sapo-
nin extraction followed by a bottom-up proteomics approach
using liquid chromatography coupled to tandem mass spec-
trometry (LC-MS/MS). The workflow was applied to positive
blood cultures with Escherichia coli and Klebsiella
pneumoniae collected prospectively in two academic hospi-
tals over a 4-month period. Of 170 positive blood cultures, 22
(12.9%) contained ESBL-positive isolates based on standard
susceptibility testing. Proteomic analysis identified CTX-M
ESBLs in 95% of these isolates directly in positive blood
cultures, whereas no false positives were found in the non-
ESBL producing positive blood cultures. The results were
confirmed by molecular characterisation of beta-lactamase
genes. Based on this proof-of-concept study, we conclude that
LC-MS/MS-based protein analysis can directly identify
extended-spectrum beta lactamases in E. coli and
K. pneumoniae positive blood cultures, and could be further
developed for application in routine diagnostics.
Keywords Proteomics . ESBL . Beta-lactamase . Blood
cultures . Mass spectrometry
Introduction
Infections caused by antibiotic resistant Gram-negative bacte-
ria are an increasing problem worldwide. In the Netherlands,
resistance towards third generation cephalosporins through
extended-spectrum beta-lactamases (ESBLs) is the most fre-
quently found antibiotic resistance of medical importance [1].
Unrecognised, infections with ESBL-producing bacteria pose
a serious threat, as they are associated with highmorbidity and
mortality rates [2]. Escherichia coli and Klebsiella
pneumoniae are reported among the main representatives of
ESBL-producing bacteria. In the Netherlands, ESBL preva-
lence is approximately 10% among infected patients [3].
Extended-spectrum beta-lactamases are a group of beta-
lactamases which can also hydrolyze third generation cepha-
losporins. The detection of these ESBL-enzymes is currently
provided indirectly by the results of standard susceptibility
testing of cultured bacteria, followed by a phenotypic confir-
mation assay or a genetic test. Direct detection of the enzyme
responsible would provide molecular information regarding
the phenotype. Protein analysis by way of mass spectrometry
has changed microbiological practice in recent years through
the introduction of Matrix-Assisted Laser Desorption
Ionisation-Time of Flight Mass Spectrometry (MALDI-TOF
MS) for species identification [4]. However, the inherent lim-
itations of these instruments such as the limited dynamic range
and resolution limit the general applicability to accurately de-
tect the presence of ESBL, particularly in identifying the na-
ture of the underlying enzyme.
Peptide analysis by bottom-up proteomics is commonly
used to directly identify proteins and can be used for in-
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depth proteomic characterisation of resistant bacteria, often
using multi-dimensional protein and/or peptide fractionation
techniques [5–7]. However, straight analysis of proteolytic
digests of total cellular protein extracts also allows to directly
identify resistance-related proteins such as beta-lactamases [8,
9]. This leads to shorter analysis times compared to compre-
hensive proteome studies while maintaining the inherent spec-
ificity of directly identifying the protein of interest. Previously
we developed such a proteomic platform for the direct detec-
tion of OXA-48 and KPC carbapenemases in bacterial cul-
tures of clinical isolates [10–12].
A significant reduction in analysis time would be achieved
when bacterial beta-lactamases could be directly analyzed in
positive blood cultures. Therefore, the aim of this study was to
develop a LC-MS/MS based bottom-up proteomics workflow
to identify ESBL-producing E. coli andK. pneumoniae direct-
ly in blood cultures and to test the performance of this
workflow in a proof-of-principle study using clinical blood
culture samples collected in a prospective study.
Materials and methods
Design of study
This study was designed to evaluate the use of proteomic
analysis by LC-MS/MS for the detection of extended-
spectrum beta lactamases directly from positive blood culture
bottles that grow E. coli or K. pneumonia, during a prospec-
tive study. Two academic centers participated in the study: the
Erasmus University Medical Center in Rotterdam and the
Leiden University Medical Center in Leiden. During a period
of 4 months (July–October 2015), all positive blood cultures
with K. pneumoniae or E. coli, were included in the study.
Comparison of sample preparation methods
Two methods were evaluated for the analysis of bacterial pro-
teins in blood cultures, serum separator tubes and a differential
lysis protocol using saponin. For this purpose, negative blood
culture bottles were spiked with different amounts of liquid
broth culture of E. coli BL21(DE3) pLysS to mimic different
bacterial densities in positive blood cultures.
Serum separator tubes feature a gel through which red
blood cells can migrate while bacteria are pelleted on top of
the gel. Four mL from a spiked blood culture bottle were
appl ied to the tubes (Becton Dickinson, Breda,
The Netherlands) and the mixture was centrifuged at 6000 g
for 10 min. Serum was removed and the pellet was washed
twice with 1 mL of phosphate buffered saline (PBS) followed
by a 5 min centrifugation at 6000 g. The bacterial pellet on top
of the gel was resuspended in 100 μL PBS and transferred to
an Eppendorf tube. The gel was rinsed with 100 μL PBS
another three times to recover any residual bacteria and this
was added to the vial. The resulting bacterial suspension was
centrifuged at 10,000 g for 1 min and the supernatant was
removed. 100 μL of 50% trifluoroethanol (TFE) solution
was added for protein extraction and solubilisation. This sus-
pension was sonicated in an ultrasound water bath for 2 min.
Suspensions were heated to 60 °C for an hour. The resulting
lysates were then subjected to protein digestion.
For the saponin protocol, 4 mL of the spiked blood culture
bottle was mixed with 1 mL of a saponin (Sigma-Aldrich,
Zwijndrecht, The Netherlands) stock solution (5% w/v, final
concentration 1% w/v). The mixture was vortexed, incubated
at room temperature for 5 min and centrifuged at 6000 g for
10min. The cell pellet was washed three times with 1 mL PBS
and centrifuged at 10,000 g for 1 min and, following the final
centrifugation step, re-suspended in 100 μL 50% TFE solu-
tion. The suspension was sonicated using an ultrasound water
bath for 2 min. Suspensions were heated at 60 °C for an hour.
The resulting lysates were stored at −80 °C until further
analysis.
Blood culture and species identification
Blood cultures were drawn as part of normal clinical routine.
A sample of 8–10 mL of blood was used per bottle (Bactec
Plus Aerobic and Bactec Plus Anaerobic, Becton Dickinson,
Breda, The Netherlands) for blood culturing (Bactec FX,
Becton Dickinson, Breda, The Netherlands). Bacterial species
in positive cultures were identified directly from 1 mL blood
culture by MALDI-TOF MS analysis (Microflex, Bruker
Daltonics, Bremen, Germany) according to an in-house devel-
oped protocol adapted from literature [13]. All positive
flagged blood cultures were stored at 4 °C and processed
within 48 h using the saponin protocol described above.
Susceptibility testing
Susceptibility testing was performed with VITEK 2
(bioMérieux, Marcy l’Etoile, France). The presence of
ESBLs was performed using the combination disk diffusion
tests (Rosco Diagnostica A/S, Taastrup, Denmark) according
to the Dutch guideline [14]. Disks used were ceftazidime
(30 μg), ceftazidime + clavulanate (30 + 10 μg), cefotaxime
(30 μg) and cefotaxime + clavulanate (30 + 10 μg). ESBL
production was considered positive if the zone diameters
around one or both of the combination disks was ≥5 mm com-
pared to the corresponding antibiotic-only disk. E-tests for
ceftazidime, cefotaxime and meropenem were performed on
Mueller Hinton E agar media according to the recommenda-
tions of EUCAST (http://www.eucast.org/clinical_
breakpoints/).
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In-solution protein digestion
Stored lysates (at −80 °C) were thawed for further processing
for bottom-up proteomics. Reduction was performed with di-
thiothreitol (DTT, final concentration 2.5 mM in 25 mM am-
monium bicarbonate) at 60 °C for 15 min. Alkylation was
performed in the dark with iodoacetamide (final concentration
5.5 mM in 25 mM ammonium bicarbonate) for 15 min.
Following alkylation the samples were digested overnight
using sequencing grade modified trypsin (12.5 ng/μl,
Promega, Leiden, The Netherlands). The next day the
resulting digests were lyophilized and reconstituted in 0.5%
trifluoroacetic acid (TFA) for pre-column trapping during LC-
MS/MS analysis.
Molecular characterisation
All ESBL positive isolates (n = 22) were analyzed for the
presence of beta-lactamase genes. An in-house real-time mul-
tiplex blaCTX-M PCR was used for analysis of the specific
CTX-M groups. For primer design, an alignment of the avail-
able blaSHV gene sequences from GenBank®was made using
the AlignX program (Vector NTI Advance 11, Invitrogen).
Primers and probes were developed in-house using Beacon
Designer (Premier Biosof t , Pa lo Al to , U.S.A.) .
Subsequently, beta-lactamase gene blaSHV was amplified
using PCR and further investigated by nucleotide sequence
analysis [15]. All primers and probes used in this study are
listed in Table 1. These molecular assays have been developed
and internally validated at the LUMC and are used in daily
routine.
LC-MS/MS analysis and data processing
Peptide mixtures were analyzed using nano reversed-phase
liquid-chromatography coupled to tandem mass spectrometry
(nano LC-MS/MS). The nano-LC system (Ultimate 3000
RSLCnano, Dionex) combines a 2-cm Acclaim PepMap 100
guard column with an Acclaim PepMap RSLC column (C18,
75 μm × 50 cm with 2 μm particles). A multi-step gradient
going from 5 to 55% B in 180 min was used (solvent A being
0.1% formic acid in water and solvent B 0.1% formic acid in
80% acetonitrile) at a rate of 300 nl min−1. Mass spectrometry
analysis was carried out on a maXis Impact UHR-TOF-MS
(Bruker Daltonics) in data dependent MS/MSmode, with pre-
cursors ranging from m/z 300–1200. After MS/MS analysis
precursors were excluded from selection dynamically for one
minute.
Raw data were converted to Mascot Generic Files (MGF)
and analyzed by database searching using the Mascot algo-
rithm (Mascot 2.5.1, Matrix Science, London, UK) using
Mascot Daemon 2.5.1. To ensure a comprehensive search of
all beta-lactamases, a custom database was prepared. This
database consists of in-silico translated reference genomes
for K. pneumoniae (http://www.ncbi.nlm.nih.gov/genome/
815?genome_assembly_id=168877) and E. coli (http://www.
ncbi.nlm.nih.gov/genome/167?genome_assembly_id=
161521), supplemented with a comprehensive list of beta-
l a c t amas e s con t i n u ed f r om th e fo rme r Lahey
database (December 2015, ftp://ftp.ncbi.nlm.nih.gov/
pathogen/betalactamases/Allele-prot.fa). Searches were
carried out with the following parameters: precursor mass
tolerance was 0.05 Da and MS/MS tolerance 0.8 Da.
Carbamidomethylcysteine was set as a fixed modification,
with methionine oxidation as variable modification. Trypsin
was designated as an enzyme with a maximum allowed num-
ber of missed cleavages of two. The False Discovery Rate
(FDR) was set at 0.01 at the peptide level based on decoy
database searches.
Results
Optimization of sample extraction
Two different sample preparation protocols were compared
with respect to the overall number of protein identifications
and the ease of use of the method. For this purpose, we used
negative blood culture bottles spiked with different amounts
of liquid broth culture of E. coli BL21(DE3) pLysS cells to
mimic different bacterial densities in positive blood cultures.
The number of successful protein identifications was
Table 1 Primers and probes used in this study
Target Forward primer Reverse primer Probe
(5′ to 3′)(5′ to 3′) (5′ to 3′)
blaSHV GCCGGTTATTCTTATTTGTCGC ATGCCGCCGCCAGTCA
blaCTX-M1 family CTGACYTKGTTAACTATAATC GTGAGMAATCAGCTTATTC CCACGTTATCGCTGTACTGTAG
blaCTX-M2 family ACCTGGTTAACTACAATC GCAGTATTGTCGCTATAC ATTGCGGAGAAACACGTTAACG
blaCTX-M9 family CCGATCTGGTTAACTACA GGCAATCAATTTGTTCATG AACACGTCAACGGCACAATG
blaCTX-M26 family CTCAGACTTGRTTAACTACA GCAGTATTATCGCTGTAC CGTCAATGGCACGATGACAT
Eur J Clin Microbiol Infect Dis
determined at 3.0 × 107 and 3.0 × 108 CFU using a sample
preparation by serum separator tubes and by differential lysis
protocol using saponin. As a reference, the protocols were also
applied to the bacterial suspensions used for inoculation of the
blood cultures, using 1.0 × 107 CFU. Results of all analyses
were searched independently against the bacterial database
and, for human proteins, against the human database.
Table 2 summarises the results for the proteomic comparisons
of both protocols. The sample containing 3.0 × 108 CFU per-
formed better in the saponin protocol. Since this procedure is
less laborious we treated all subsequent positive blood cul-
tures by the saponin protocol. A number of variables of the
saponin lysis protocol were tested including centrifugation
speed and duration, saponin concentration and number of
washing steps. No significant improvements were made and
the protocol therefore remained unchanged.
Blood culture collection and susceptibility testing
During a period of four months, positive blood cultures with
E. coli or K. pneumoniae were collected prospectively
(Table 3). In total, 170 positive blood cultures were collected.
Of these, 125 (73.5%) contained E. coli and 45 (26.5%)
K. pneumoniae. Following susceptibility testing of cultured
i s o l a t e s , 2 2 i s o l a t e s ( 1 2 . 9% , 18 E . c o l i a nd
4 K. pneumoniae) were confirmed as ESBL-positive with
the combination disk diffusion test.
Results from bottom-up proteomics analysis
All 22 blood cultures with ESBL positive isolates were select-
ed for proteomic analysis, as well as 44 randomly selected
ESBL negative blood cultures. Preparation of the 66 blood
cultures for LC-MS/MS analysis was performed blind with
regards to the results of the phenotypic testing. Following
LC-MS/MS analysis, the resulting spectra were searched
against the in-house generated database (see materials and
methods) featuring a comprehensive list of beta-lactamases
as well as K. pneumoniae and E. coli proteomes. In a typical
analysis of one positive blood culture bottle, 400–800 bacte-
rial proteins were identified. Table 4 summarises the results
for the phenotypically ESBL positive blood cultures (n = 22).
In all results obtained by MS, the detected β-lactamase was
always in the top 10% of the total number of identified bacte-
rial proteins in a sample, sorted by identification score. In 21
out of 22 of the ESBL positive isolates a cefotaximase (CTX-
M) was identified. Protein sequence coverage based on iden-
tified peptides varied from 38% to 88%. This coverage allows
for the mapping of the identified cefotaximases into one of six
established lineages [16], named after their archetypical en-
zymes. In our collection, only members of groups CTX-M-1
and CTX-M-9 were found. In one K. pneumoniae isolate
(Table 4, number 15) no cefotaximase was found. A SHV type
beta-lactamase was identified with 33% coverage (Fig. 1).
Like with the cefotaximases, this protein was a top 10% iden-
tification among all bacterial proteins identified. From 148
ESBL-negative K. pneumonia or E. coli positive blood cul-
tures, 44 were randomly selected and also analyzed by LC-
MS/MS. In none of these samples, extended-spectrum beta-
lactamases were found.
Molecular characterisation of ESBL positive isolates
To confirm the identity of the ESBLs identified with LC-MS/
MS based proteomics, molecular characterisation of all phe-
notypically ESBL positive isolates was performed (Table 4).
All CTX-M identifications were verified with PCR. In isolate
15, the LC-MS/MS identified a SHV-enzyme which was con-
firmed by PCR as an ESBL, namely, SHV-12. Three non-
ESBL SHV beta-lactamases were identified by PCR in the
K. pneumoniae isolates.
Discussion
In this study we developed a novel proteomic workflow for
the direct identification of ESBLs in positive blood culture
bottles. To evaluate the performance of our approach, a
proof-of-principle prospective study was performed in two
academic hospitals. In 22 positive blood cultures with pheno-
typically ESBL producing E. coli or K. pneumoniae, we iden-
tified 21 isolates containing a CTX-M and one isolate contain-
ing a SHV beta-lactamase, although the latter could not un-
ambiguously be identified because the single peptide neces-
sary to discriminate between an ESBL and non-ESBLwas not
identified. In the set of positive blood cultures with ESBL-
negative E. coli or K. pneumoniae, no ESBLs were identified
by LC-MS/MS analysis. This demonstrates a 95% sensitivity
and 100% specificity of the workflow to directly identify these
beta-lactamases in positive blood cultures.
Table 2 Comparison of the number of protein identifications using two
different sample preparation protocols for LC-MS/MS analysis of
bacterial protein extracts from blood cultures
Sample Bacterial proteins Human proteins
Reference 566 16
Saponin 3.0 107 CFU 196 165
Saponin 3.0 108 CFU 477 135
SST 3.0 107 CFU 199 145
SST 3.0 108 CFU 288 82
Samples were spiked with 3.0 107 or 3.0 108 CFU obtained from liquid
broth culture. Saponin: differential lysis protocol. SST: Serum separator
tube protocol. As a reference, a suspension containing 1.0 107 CFU was
prepared from the same liquid culture that was used to spike the negative
blood cultures
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Of 170 positive blood cultures collected in two academic
hospitals, 22 (12.9%) contained ESBL producing bacteria be-
longing to E. coli or K. pneumoniae. This percentage is higher
than previously described in The Netherlands [3], with
cefotaxime/ceftriaxone resistances reported to be 5% and 7%
for E. coli and K. pneumoniae, respectively. However, these
data were based on a larger number of laboratories, including
laboratories serving non-university hospitals and general prac-
titioners. All collected samples in our study showed full
meropenem susceptibility, in agreement with the low preva-
lence rate of carbapenemase producing Gram-negatives in
The Netherlands [3].
In the proteomic analysis of the clinical isolates, 21 out of
22 (95%) of the phenotypically ESBL-positive isolates
Table 3 Collection of positive
blood cultures Origin Positive blood cultures
E. coli no. ESBL+ (%) K. pneu. no. ESBL+ (%) Total no. ESBL+ (%)
ErasmusMC 57 8 (14.0) 22 3 (11.1) 79 11 (13.9)
LUMC 68 10 (14.7) 23 1 (4.3) 91 11 (12.1)
Sum 125 18 (14.4) 45 4 (8.9) 170 22 (12.9)
Samples were collected in two university medical centers in the Netherlands: the Erasmus MC in Rotterdam and
the Leiden UniversityMedical Center (LUMC) in Leiden. Presence of ESBLs was determined using phenotypical
susceptibility testing
Table 4 Resistance profile and LC-MS/MS-based ESBL identification in ESBL positive blood cultures
Culture Origin Species Resistance profile β-lactamase detection
MIC (mg/L) LC-MS/MS PCR
CTX CZD Mero
1 LUMC E. coli >32 8 0.023 Group 1 CTX-M Gr 1 CTX-M
2 LUMC E. coli >32 24 0.032 Group 1 CTX-M Gr 1 CTX-M
3 LUMC E. coli >32 3 0.023 Group 9 CTX-M Gr 9 CTX-M
4 LUMC E. coli >32 3 0.023 Group 9 CTX-M Gr 9 CTX-M
5 LUMC E. coli >32 8 0.012 Group 1 CTX-M Gr 1 CTX-M
6 LUMC K. pneumoniae >32 32 0.032 Group 1 CTX-M Gr 1 CTX-M; SHV-1
7 LUMC E. coli >32 1.5 0.023 Group 1 CTX-M Gr 1 CTX-M
8 LUMC E. coli >32 4 0.023 Group 1 CTX-M Gr 1 CTX-M
9 LUMC E. coli >32 6 0.023 Group 1 CTX-M Gr 1 CTX-M
10 LUMC E. coli >32 2 0.023 Group 1 CTX-M Gr 1 CTX-M
11 LUMC E. coli >32 6 0.023 Group 1 CTX-M Gr 1 CTX-M
12 Erasmus MC E. coli >32 32 0.023 Group 1 CTX-M Gr 1 CTX-M
13 Erasmus MC E. coli 8 0.25 0.023 Group 9 CTX-M Gr 9 CTX-M
14 Erasmus MC E. coli >32 6 0.023 Group 1 CTX-M Gr 1 CTX-M
15 Erasmus MC K. pneumoniae 8 32 0.032 SHVa SHV-12
16 Erasmus MC E. coli >32 0.75 0.012 Group 9 CTX-M Gr 9 CTX-M
17 Erasmus MC K. pneumoniae >32 8 0.032 Group 1 CTX-M Gr 1 CTX-M; SHV-11
18 Erasmus MC E. coli >32 12 0.032 Group 1 CTX-M Gr 1 CTX-M
19 Erasmus MC K. pneumoniae >32 48 0.094 Group 1 CTX-M Gr 1 CTX-M; SHV-1
20 Erasmus MC E. coli >32 8 0.023 Group 1 CTX-M Gr 1 CTX-M
21 Erasmus MC E. coli >32 8 0.023 Group 1 CTX-M Gr 1 CTX-M
22 Erasmus MC E. coli >32 48 0.023 Group 1 CTX-M Gr 1 CTX-M
CTX cefotaxime, CZD ceftazidime, Mero meropenem
MIC (mg/L) values were determined using E-tests.a TheMS/MS data was inconclusive about the positive identification of this SHVas an ESBL because
the single peptide necessary to discriminate between an ESBL and non-ESBLwas not identified. The sequencing of the PCR product confirmed that this
was an ESBL. See text for further explanation
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contained a CTX-M ESBL. Cefotaximases are the most wide-
spread ESBLs and a high representation in this study was
expected [16, 17]. In our study, the CTX-M enzymes
belonged to group 1 (17 out of 21; 81%) and group 9 (4 out
of 21; 19%). This is in accordance with other reports [18].
Specifically, CTX-M-15 (group 1) and CTX-M-14 (group 9)
are among the most prevalent enzymes [19]. Notably, in our
collection there was no relation between MIC and ESBL type,
especially not for ceftazidime.
Full sequence coverage is necessary to pinpoint a protein
identification to a specific ESBL but in complex samples with
the use of only one proteolytic enzyme, this is not feasible.
Obviously, peptide fractionation or additional experiments
with another proteolytic enzyme could improve the specificity
of the identification. However, we opted for a simple sample
preparation protocol, which is mostly constrained time-wise
by the proteomic digestion step. In our approach, the sequence
coverage among ESBLs in phenotypically positive isolates
ranged between 38% and 88%. This coverage is in-depth
enough to classify the enzymes into phylogenetic groups, such
as with the cefotaximases, but single variants cannot be dis-
tinguished using this method. This is important in
distinguishing beta-lactamases that have reported broad and
extended-spectrum activities, based on small permutations.
For example, one blood culture sample contained a SHV be-
ta-lactamase. The sequence coverage obtained by LC-MS/MS
analysis was not sufficient to distinguish between a broad and
extended-spectrum beta-lactamase. The amino acid at position
238 is instrumental in cephalosporin resistance in SHV vari-
ants and the tryptic peptide covering this amino acid is there-
fore necessary for the unambiguous assignment of the ESBL
status [20]. The corresponding tryptic peptides of the SHV-1
(broad spectrum) and SHV-2 (extended-spectrum) are
TGAGER and TGASER, respectively. While the double-
charged state would be within the mass range of the mass
spectrometer, sensitivity in this low mass range is not optimal
and short peptides can also be difficult to retain and separate in
liquid chromatography. A more targeted approach might be
more suitable for such specific peptides [21]. Importantly, the
LC-MS/MS identified SHV beta-lactamase in isolate 15 was
confirmed to be an ESBL (SHV-12) by our PCR and sequence
analysis. The PCR analyses revealed three additional SHV
beta-lactamases which were not identified in the proteomics
analysis. Sequence analysis demonstrated that the three addi-
tional SHV beta-lactamases were non-ESBLs (SHV-1, SHV-
11) and could have been missed in our proteomic analysis due
to lower abundance as compared to the ESBL-SHV.
Therefore, as it stands now, identifying a SHV with high ex-
pression combined with the phenotypical results indicates an
ESBL-SHV, but our proteomic data was not sufficient to un-
ambiguously draw this conclusion.
In this proof-of-principle study, ESBLs from the CTX-M
group were easy to identify. PCR-based methods have been
successfully applied for the identification of ESBLs in blood
cultures [22, 23], and in our study, the CTX-M PCR results
fully correlated with the proteomics results. The aim of our
prospective study was to demonstrate the applicability in nor-
mal routine, and therefore we detected mainly CTX-M ESBL.
Larger clinical sample cohorts and spiking experiments with
other ESBL/carbapenemase producing bacteria in negative
blood cultures are necessary to demonstrate the general appli-
cability of our approach. Based on the results of our previous
study, this workflow should also be suitable for the detection
of OXA-48 and KPC beta-lactamases directly in blood cul-
tures [11]. The sample preparation is highly similar and over-
all proteome and protein coverage was significantly higher
using this nanoLC platform. Moreover, the mass spectromet-
ric analysis part of our workflow can be easily exchanged for
other high-end mass spectrometry analysers (such as
Orbitraps) with even higher speed and sensitivities. As with
all genetic methods, a positive identification does not guaran-
tee protein expression. More sensitive proteomic analysis
could therefore give some insight into our problem to detect
the additional non-ESBL lactamases with our proteomics
workflow.
Apart from genetic tests, there are alternative methods to
detect the presence of ESBLs in blood culture bottles. Oviaño
et al. monitored ESBL activity directly from blood cultures
using MALDI-TOF MS by measuring antibiotic hydrolysis
[24]. Reported sensitivity and specificity are high, suggesting
that such an approach can be used as an alternative to tradi-
tional susceptibility testing. Moreover, hydrolysis based
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Fig. 1 Coverage of SHV-1 sequence. Identified peptides by LC-MS/MS
analysis are highlighted when they matched to the sequence of the SHV-1
beta-lactamase. The glycine at Ambler position 238 (underlined) is spe-
cific for the SHV-1 sequence, while SHV-2 type extended-spectrum beta-
lactamases have a serine in this position. This peptide was not observed in
LC-MS/MS analysis making it not possible to distinguish between the
beta-lactamase types
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assays using reporter molecules are mentioned in literature
and available as commercial kits [25, 26]. Even though hydro-
lysis based tests are useful, interpretation can be difficult in
case of enzymes with a lower activity, and they provide no
insight in the identity of the ESBL. In comparisonwith genetic
and hydrolysis based methods, our workflow allows the direct
identification of the enzyme responsible, providing molecular
information about the phenotype.
Overall, in this proof-of-principle prospective study we
demonstrate the direct identification of an ESBL in all blood
cultures that contained bacteria positive for a CTX-M type
ESBL. The method is specific enough to recognise specific
groups of CTX-M ESBL. To improve on this proof-of-
principle study in the future a number of aspects need further
exploration. Among these, shortening the time-to-report and
automation of the procedure are among the most critical [27,
28]. With this in mind, the developed platform can be used in
the future for the direct identification of expressed beta-
lactamases in blood cultures which provides detailed insight
into the antibiotic resistance mechanism.
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